quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·3d
PRRelease
Allarity Therapeutics Inc. logo

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

ALLR· Allarity Therapeutics Inc.
Health Care
Original source

Companies

  • ALLR
    Allarity Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jul 28UpdateAscendiant Capital Markets$9.00

Related

  • SEC2d
    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • SEC13d
    SEC Form PRE 14A filed by Allarity Therapeutics Inc.
  • SEC23d
    Allarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR24d
    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress
  • SEC24d
    SEC Form 10-K filed by Allarity Therapeutics Inc.
  • SEC46d
    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • SEC49d
    Allarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
  • PR49d
    Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022